These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis. Xue WX; Zhang MY; Rui Li ; Liu X; Yin YH; Qu YQ Biomed Res Int; 2020; 2020():9601876. PubMed ID: 32724822 [TBL] [Abstract][Full Text] [Related]
23. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study. Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143 [TBL] [Abstract][Full Text] [Related]
24. Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC). Abdipourbozorgbaghi M; Vancura A; Radpour R; Haefliger S Br J Cancer; 2024 Nov; 131(8):1350-1362. PubMed ID: 39215192 [TBL] [Abstract][Full Text] [Related]
25. Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression. Grimolizzi F; Monaco F; Leoni F; Bracci M; Staffolani S; Bersaglieri C; Gaetani S; Valentino M; Amati M; Rubini C; Saccucci F; Neuzil J; Tomasetti M; Santarelli L Sci Rep; 2017 Nov; 7(1):15277. PubMed ID: 29127370 [TBL] [Abstract][Full Text] [Related]
26. Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer. Trakunram K; Chaniad P; Geater SL; Keeratichananont W; Chittithavorn V; Uttayamakul S; Buya S; Raungrut P; Thongsuksai P Cancer Biol Med; 2020 Aug; 17(3):652-663. PubMed ID: 32944397 [No Abstract] [Full Text] [Related]
27. [TCM Combined Western Medicine Treatment of Advanced NSCLC: a Preliminary Study of mIRNA Expression Profiles]. Li YB; Lin LZ; Guan JS; Chen CM; Zuo Q; Lin BQ Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Sep; 36(9):1076-1081. PubMed ID: 30645846 [TBL] [Abstract][Full Text] [Related]
28. Circular RNA circ_0001649 acts as a prognostic biomarker and inhibits NSCLC progression via sponging miR-331-3p and miR-338-5p. Liu T; Song Z; Gai Y Biochem Biophys Res Commun; 2018 Sep; 503(3):1503-1509. PubMed ID: 30029881 [TBL] [Abstract][Full Text] [Related]
29. Tumor-derived circulating exosomal miR-342-5p and miR-574-5p as promising diagnostic biomarkers for early-stage Lung Adenocarcinoma. Han Z; Li Y; Zhang J; Guo C; Li Q; Zhang X; Lan Y; Gu W; Xing Z; Liang L; Li M; Mi S Int J Med Sci; 2020; 17(10):1428-1438. PubMed ID: 32624699 [TBL] [Abstract][Full Text] [Related]
30. Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer. Zhang ZJ; Song XG; Xie L; Wang KY; Tang YY; Yu M; Feng XD; Song XR Exp Biol Med (Maywood); 2020 Oct; 245(16):1428-1436. PubMed ID: 32741216 [TBL] [Abstract][Full Text] [Related]
31. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Wu C; Cao Y; He Z; He J; Hu C; Duan H; Jiang J Tohoku J Exp Med; 2014 Feb; 232(2):85-95. PubMed ID: 24531034 [TBL] [Abstract][Full Text] [Related]
32. A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer. Zhou C; Chen Z; Zhao L; Zhao W; Zhu Y; Liu J; Zhao X J Clin Lab Anal; 2020 Nov; 34(11):e23505. PubMed ID: 33463758 [TBL] [Abstract][Full Text] [Related]
33. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis. Song Z; Jia G; Ma P; Cang S Life Sci; 2021 Jul; 276():119399. PubMed ID: 33781830 [TBL] [Abstract][Full Text] [Related]
34. Upregulated Expression of Serum Exosomal microRNAs as Diagnostic Biomarkers of Lung Adenocarcinoma. Feng M; Zhao J; Wang L; Liu J Ann Clin Lab Sci; 2018 Nov; 48(6):712-718. PubMed ID: 30610040 [TBL] [Abstract][Full Text] [Related]
35. Downregulation of serum exosomal miR-216b predicts unfavorable prognosis in patients with non-small cell lung cancer. Liu W; Liu J; Zhang Q; Wei L Cancer Biomark; 2020; 27(1):113-120. PubMed ID: 31771047 [TBL] [Abstract][Full Text] [Related]
36. Serum exosomal miR-1269a serves as a diagnostic marker and plays an oncogenic role in non-small cell lung cancer. Wang X; Jiang X; Li J; Wang J; Binang H; Shi S; Duan W; Zhao Y; Zhang Y Thorac Cancer; 2020 Dec; 11(12):3436-3447. PubMed ID: 33107700 [TBL] [Abstract][Full Text] [Related]
37. Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Halvorsen AR; Sandhu V; Sprauten M; Flote VG; Kure EH; Brustugun OT; Helland Å Acta Oncol; 2018 Sep; 57(9):1225-1231. PubMed ID: 29683761 [TBL] [Abstract][Full Text] [Related]
38. Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients. Zhang Y; Xu H J Clin Lab Anal; 2020 Jun; 34(6):e23237. PubMed ID: 32061007 [TBL] [Abstract][Full Text] [Related]
39. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. Lu C; Shan Z; Hong J; Yang L Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966 [TBL] [Abstract][Full Text] [Related]
40. Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A. Gu G; Hu C; Hui K; Zhang H; Chen T; Zhang X; Jiang X Int J Nanomedicine; 2021; 16():6329-6343. PubMed ID: 34556984 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]